18.47
0.05 (0.27%)
| Penutupan Terdahulu | 18.42 |
| Buka | 18.53 |
| Jumlah Dagangan | 176,981 |
| Purata Dagangan (3B) | 237,244 |
| Modal Pasaran | 564,938,176 |
| Harga / Jualan (P/S) | 2.03 |
| Harga / Buku (P/B) | 0.500 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -59.39% |
| Margin Operasi (TTM) | -23.81% |
| EPS Cair (TTM) | -5.52 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -15.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.88% |
| Nisbah Semasa (MRQ) | 4.41 |
| Aliran Tunai Operasi (OCF TTM) | 10.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.43 M |
| Pulangan Atas Aset (ROA TTM) | -4.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -14.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | Fulgent Genetics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 1.75 |
|
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 32.31% |
| % Dimiliki oleh Institusi | 54.23% |
| Julat 52 Minggu | ||
| Median | 22.00 (19.11%) | |
| Jumlah | 1 Pegang | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 11 Nov 2024 | 22.00 (19.11%) | Pegang | 20.04 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Nov 2024 | Pengumuman | Fulgent Reports Third Quarter 2024 Financial Results |
| 05 Nov 2024 | Pengumuman | Fulgent to Participate in Upcoming Conferences |
| 31 Oct 2024 | Pengumuman | Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans¹ |
| 17 Oct 2024 | Pengumuman | Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |